Oncology
Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
FDA has approved belzutifan plus lenvatinib after PD-1 or PD-L1 therapy in advanced clear-cell renal cell carcinoma. The combination improved progression-free survival and response against cabozantinib. Overall survival did not cross the statistical line.
Medical Debt Is Becoming a Cancer Stage
Lymphoma Is Testing How Far Chemo-Free Care Can Go
Cancer Survivorship Standards Are Still Mostly Paper
Breast Cancer Immunotherapy Has a New Problem: Who Gets the Second Checkpoint?
Small-Cell Lung Cancer Gets an ADC Signal With Teeth
Pancreatic Cancer Gets a New Radiation Rulebook
Ovarian Cancer Survival Is Still Being Written by Where Patients Live
Myeloma Gets an Accelerated Approval. The Endpoint Is the Politics.
ctDNA Is Becoming a Surveillance Policy, Not Just a Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases